Valuation and Targets, page-294

My favourite chart (from Amibroker, my code) looks like

The bottom chart blue line shows recent lows, the red recent highs, and the yellow tracking between.
As of Friday it looks like a range between 2.94 and 3.30+. You can see the effect of shorting (red candles), and the absence of news.
The recent great pickup by
@3gig4me @Agent-86Big
on another thread
https://www.mstaccess.com.au/research-notes/
showed a timeline which is a little less definite or pushed out from what we were expecting/hoping for.

• Potential Near-Term Catalysts•
• Q2CY20- Further results from Australian SAS patients
• Early 2020– Submission of KOA Investigational New Drug Application to FDA
• Mid CY20 - Results of US EAP of 10 ex-NFL players
• Mid CY20 – Start of the Phase III pivotal clinical trial in OA
• Q3CY20 – Australian provisional approval and revenues for iPPS for KOA
• CY20 - Pivotal Phase II/III trial in MPS to begin in US
• CY20 – Treatment of MPS patients in Australia via the SAS
• CY21 – Phase III KOA and MPS patient trials’ results release

So while there may be upside to $4.3, the risk of pull backs to 2.94 is high until there is good news. IMO only, DYOR.
I am fully invested at this point, may switch sentiment to hold, thinking about that in context of overall market.